On the other hand, PDGF-Rβ inhibitors such as ripretinib [55] and sorafenib [56] have been approved for the treatment of gastrointestinal stromal tumor and renal cell carcinoma, respectively. Here, PDGFRB is linked to hereditary clear cell renal cell carcinoma.